Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B3 | P37058 | 7/20 | 0.67 |
| ▸ | THRA | P10827 | 6/20 | 0.67 |
| ▸ | THRB | P10828 | 6/20 | 0.67 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.55 |
| ▸ | HTR7 | P34969 | 1/20 | 0.54 |
| ▸ | STS | P08842 | 4/20 | 0.54 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.53 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.53 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.53 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27455127 | 1.00 | HSD17B3 (0.67) | HSD17B3THRATHRBS1PR5HTR7 | |
| SCHEMBL7758945 | 1.00 | HSD17B3 (0.67) | HSD17B3THRATHRBS1PR5HTR7 | |
| SCHEMBL15743522 | 1.00 | HSD17B3 (0.67) | HSD17B3THRATHRBS1PR5HTR7 | |
| SCHEMBL13085794 | 0.87 | HSD17B3 (0.85) | HSD17B3THRATHRBHTR7STS | |
| SCHEMBL13085847 | 0.87 | HSD17B3 (0.85) | HSD17B3THRATHRBHTR7STS | |
| SCHEMBL11490234 | 0.87 | THRA (0.77) | HSD17B3THRATHRBS1PR5 | |
| SCHEMBL7934415 | 0.87 | THRA (0.77) | HSD17B3THRATHRBS1PR5 | |
| SCHEMBL15199330 | 0.86 | HSD17B3 (0.71) | HSD17B3THRATHRBS1PR5HTR7 | |
| SCHEMBL12303994 | 0.86 | HSD17B3 (0.71) | HSD17B3THRATHRBS1PR5HTR7 | |
| SCHEMBL507985 | 0.85 | HSD17B3 (0.62) | HSD17B3THRATHRBHTR7STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240408214-A1 | NANOPARTICULATE MONOBENZONE FOR TREATING MELANOMA | NORTHWESTERN UNIVERSITY | 2024-12-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240408214-A1 | NANOPARTICULATE MONOBENZONE FOR TREATING MELANOMA | TYR, CD47, SDHB | HSD17B3 2325/4885THRA 3668/4885THRB 2073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.